Crinetics Pharmaceuticals, Inc. (CRNX): Price and Financial Metrics
CRNX Stock Summary
- Crinetics Pharmaceuticals Inc's stock had its IPO on July 18, 2018, making it an older stock than merely 7.18% of US equities in our set.
- CRNX's price/sales ratio is 7,992.06; that's higher than the P/S ratio of 99.68% of US stocks.
- As for revenue growth, note that CRNX's revenue has grown -94.05% over the past 12 months; that beats the revenue growth of merely 1.03% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Crinetics Pharmaceuticals Inc, a group of peers worth examining would be ATOM, ETON, ARNA, CRSP, and VNRX.
- Visit CRNX's SEC page to see the company's official filings. To visit the company's web site, go to www.crinetics.com.
CRNX Stock Price Chart Interactive Chart >
CRNX Price/Volume Stats
| Current price | $17.30 | 52-week high | $23.70 |
| Prev. close | $17.18 | 52-week low | $11.61 |
| Day low | $17.02 | Volume | 150,260 |
| Day high | $18.11 | Avg. volume | 142,793 |
| 50-day MA | $16.18 | Dividend yield | N/A |
| 200-day MA | $14.98 | Market Cap | 571.40M |
Crinetics Pharmaceuticals, Inc. (CRNX) Company Bio
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is based in San Diego, California.
Latest CRNX News From Around the Web
Below are the latest news stories about Crinetics Pharmaceuticals Inc that investors may wish to consider to help them evaluate CRNX as an investment opportunity.
Crinetics Pharmaceuticals Stock Is Showing Strong Insider InterestClinical-stage pharmaceutical company Crinetics Pharmaceuticals Inc. (CRNX) has seen a key corporate insider snap up shares recently. Regulations require corporate insiders to make their trading activity public, and their actions could signal to investors that now is the time to get in on the action. In the last 12 days, corporate insider Perceptive Advisors LLC, which owns a more than 10% stake in the company, has bought $5 million worth of Crinetics shares. (See Crinetics stock analysis on TipRanks) On March 31, H. C. Wainwright analyst Douglas Tsao reiterated a Buy rating on the stock with a $30 price target (81.3% upside potential). |
Crinetics Pharmaceuticals Announces Closing of Common Stock OfferingSAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has closed its previously announced underwritten follow-on offering of 4,562,044 shares of its common stock at a price to the public of $16.44 per share. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $75.0 million. Investors in the offering included Deep Track Capital, Bain Capital Life Sciences, and Driehaus Capital Management, with participation from other new and existing stockhol... |
What Type Of Shareholders Own The Most Number of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares?A look at the shareholders of Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) can tell us which group is most powerful... |
Crinetics Pharma raises $75M via equity offeringCrinetics Pharmaceuticals (CRNX) has priced its public offering of ~4.6M common shares at $16.44/share, for expected gross proceeds of ~$75M. Net proceeds will be used to fund the development of paltusotine and other R&D programs, for working capital and general corporate purposes. SVB Leerink is acting as sole bookrunning manager.Closing... |
Crinetics Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call PresentationThe following slide deck was published by Crinetics Pharmaceuticals, Inc. in conjunction with their 2020 Q4 earnings call.... |
CRNX Price Returns
| 1-mo | 6.53% |
| 3-mo | 13.67% |
| 6-mo | 24.10% |
| 1-year | -6.59% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 22.61% |
| 2020 | -43.76% |
| 2019 | -16.34% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching CRNX
Want to do more research on Crinetics Pharmaceuticals Inc's stock and its price? Try the links below:Crinetics Pharmaceuticals Inc (CRNX) Stock Price | Nasdaq
Crinetics Pharmaceuticals Inc (CRNX) Stock Quote, History and News - Yahoo Finance
Crinetics Pharmaceuticals Inc (CRNX) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...